CN104592352A - HGG (Human Gammaglobulin) polypeptide in combination with tissue specificity of cerebral arterial thrombosis and application thereof - Google Patents
HGG (Human Gammaglobulin) polypeptide in combination with tissue specificity of cerebral arterial thrombosis and application thereof Download PDFInfo
- Publication number
- CN104592352A CN104592352A CN201510011387.5A CN201510011387A CN104592352A CN 104592352 A CN104592352 A CN 104592352A CN 201510011387 A CN201510011387 A CN 201510011387A CN 104592352 A CN104592352 A CN 104592352A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- hgg
- phage
- cerebral infarction
- tissue specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 96
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 77
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 75
- 206010008092 Cerebral artery thrombosis Diseases 0.000 title abstract 5
- 108010074605 gamma-Globulins Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000012216 screening Methods 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 20
- 238000003384 imaging method Methods 0.000 claims abstract description 17
- 239000003068 molecular probe Substances 0.000 claims abstract description 15
- 230000008685 targeting Effects 0.000 claims abstract description 12
- 108010067902 Peptide Library Proteins 0.000 claims abstract description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 39
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 38
- 210000004556 brain Anatomy 0.000 claims description 18
- 230000000302 ischemic effect Effects 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- 230000010412 perfusion Effects 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 12
- 210000003462 vein Anatomy 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 10
- 206010002091 Anaesthesia Diseases 0.000 claims description 8
- 230000037005 anaesthesia Effects 0.000 claims description 8
- 210000005240 left ventricle Anatomy 0.000 claims description 7
- 238000002823 phage display Methods 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000005481 NMR spectroscopy Methods 0.000 claims description 3
- 238000001311 chemical methods and process Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 230000009871 nonspecific binding Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 210000001995 reticulocyte Anatomy 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 210000000115 thoracic cavity Anatomy 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000000324 neuroprotective effect Effects 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 206010008089 Cerebral artery occlusion Diseases 0.000 abstract 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 abstract 2
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 48
- 230000002490 cerebral effect Effects 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 206010008190 Cerebrovascular accident Diseases 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000012797 qualification Methods 0.000 description 9
- 208000032382 Ischaemic stroke Diseases 0.000 description 8
- 210000000269 carotid artery external Anatomy 0.000 description 7
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002725 isoflurane Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 3
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000002597 diffusion-weighted imaging Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150024923 da gene Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses HGG (Human Gammaglobulin) polypeptide in combination with the tissue specificity of cerebral arterial thrombosis. The invention relates to a method for obtaining the polypeptide. The method comprises the following steps: carrying out in-vivo selection of a mouse MCAO (Middle Cerebral Artery Occlusion) cerebral arterial thrombosis model by adopting an in-vivo phage display peptide library screening technology so as to obtain phage clones in combination with cerebral arterial thrombosis tissue; and randomly selecting the plurality of phage clones to sequence, and authenticating the in-vivo combination specificity of HGG peptide and coded phage clones HGG-M13 thereof. The invention further relates to application of the polypeptide in preparation of a high-sensitivity imaging molecular probe and a targeting delivery neuroprotective drug for cerebral stroke. The polypeptide can be synthesized through an artificial method; the polypeptide is low in molecular weight, high in activity and penetrating power, good in specificity and low in toxicity, and has good tissue targeting of cerebral arterial thrombosis in vivo; and therefore, the polypeptide is applicable to serving as a carrier of the high-sensitivity imaging molecular probe and the targeting delivery neuroprotective drug.
Description
Technical field
The invention belongs to protein and peptide technical field, relate to a kind of and pathological tissue specific binding peptides, particularly a kind of HGG polypeptide be combined with cerebral infarction tissue specificity.The invention still further relates to the method for the screening of this polypeptide and preparation, and this polypeptide is preparing the application on cerebral infarction molecular imaging probe.
Background technology
Cerebral apoplexy is a kind of cerebral blood circulation obstacle disease of unexpected onset, and it is disabled reason in the global second cause of death and first place, the survivor's permanent disability about about half.CDC data presentation cerebral apoplexy Ye Shi China disables first place reason and " number one killer ", and China's cerebral apoplexy patient more than 700 ten thousand, sickness rate rises 8.7% every year.
Patients with cerebral apoplexy treatment needs fast quick-recovery cerebral blood flow, rescues ischemic tissue of brain, unique effectively methods for the treatment of is revascularization so far, and rt-PA (rt-PA) curative effect is time-dependent manner, therapeutic time window is short, and the current U.S. only has 5%, China only has 1.2% patient can obtain effective logical treatment again.In many cases, not only the intracranial vessel opening obturation can not make patient benefit, even harmful, and reason comprises patient without the reperfusion injury etc. that secondary thrombus in Penumbra zone, brain microcirculation deposits and revascularization is adjoint." gold standard " that instruct cerebral apoplexy Early thrombolysis to treat at present is positron emission computerized tomography imaging (PET), but PET spatial resolution is low, sweep velocity is slow, somewhat expensive and popularity rate is low etc. that shortcoming limits its clinical application.Perfusion weighted imaging/the diffusion-weighted imaging (PWI/DWI) of nuclear magnetic resonance (MRI) not matching method starts clinical the thromboembolism treatment being used to guide acute ischemic stroke extreme early, but this method had both over-evaluated infarct, over-evaluate again Penumbra zone, judged validity, the accuracy of thrombolysis according to it and still need to be studied further to the directive function for the treatment of.Therefore, developing highly sensitive instructs the molecular probe of the thromboembolism treatment of acute ischemic stroke extreme early then to seem particularly important.
The treatment of nerve protection medicine to patients with cerebral apoplexy of developing for cerebral infarction has revolutionary significance.Douglas J.Cook reports that PSD protein 95 (PSD-95) inhibitor can reduce cynomolgus monkey cerebral infarction and organize area, neuroprotective function damage.And if send this kind of neuroprotective quasi-molecule by targeted peptide section and be expected to realize cerebral infarction and organize better drug-rich, reach more significant Neuroprotective effect.
Country " 12 " planning explicitly points out, and in biological medicament field, emphasis is supported monoclonal antibody drug, novel gene engineering recombinant protein and polypeptide drugs, gene therapy medicament, new generation vaccine etc.Polypeptide drugs can be synthesized by manual method, because the features such as its molecular weight is little, activity is high, penetration power is strong, specificity is high, toxicity is low make it have significant application value in oncotherapy.At present, the polypeptide drug of the granted listing in the whole world more than 50, as Leuprolide salable on current world market, gray(Gy) woods, buserelin, metakentrin antagonist etc.At present, have 140 polypeptide drugs in clinical studies, and the polypeptide drug in clinical front development reaches 500 to 600, the world market scale of 2010 years polypeptide drugs is about 13,000,000,000 dollars.Aspect, domestic market, the market sales revenue of China's polypeptide drugs rises to 194.79 hundred million yuan in 2009 from 2006 110.82 hundred million yuan, and compound annual growth rate reaches 20.68%.
At present, the polypeptide of target cerebral infarction tissue is not also had.This polypeptide obtains and instructs the molecular probe of the thromboembolism treatment of acute ischemic stroke extreme early and targeted delivery neuroprotective class medicine all to have important using value to reach better curative effect to exploitation highly sensitive.
Summary of the invention
Goal of the invention: the object of the invention is, for the present situation lacking cerebral infarction tissue specificity target polypeptide, to provide a kind of HGG polypeptide be combined with cerebral infarction tissue specificity.
Another object of the present invention there is provided the screening method of above-mentioned HGG polypeptide.
Another object of the present invention is that this HGG polypeptide conjugated magnetic nano material is built specific molecular probes, in vivo horizontally through specificity and the function of this probe of MRI imaging in evaluation.
The present invention utilizes bioinformatics method to analyze the physico-chemical property of aforementioned polypeptides.
The present invention is by the targeting of comprehensive, multi-level qualification polypeptide: phage-peptide level, by with body in feed back after phage titre to measure and immunofluorescence dyeing identifies the monoclonal specificity of phage, by the cell type specificity of this phage of Double immunofluorescence experimental verification-peptide combination; In improvement on synthesis is horizontal, identified the ischemic tissue of brain targeting of this polypeptide by immunofluorescence experiment.
Technical scheme: in order to solve the problems of the technologies described above, the invention provides a kind of HGG polypeptide be combined with cerebral infarction tissue specificity, and the aminoacid sequence of described HGG polypeptide is as shown in SEQ ID NO:1.
Above-mentioned HGG polypeptide molecular weight is 800.9, and theoretical iso-electric point is 8.75, and being by 113 atomic buildings, is 3.5h in the mammiferous reticulocyte transformation period, and this polypeptide liposoluble coefficient is 97.14, and overall average wetting ability is-0.257.
Above-mentioned HGG polypeptide is obtained by phage display peptide library triage techniques in body, and by a large amount of stdn synthesis of chemical process.
The screening method of above-mentioned HGG polypeptide, comprises the following steps:
1) MCAO model mouse builds;
2) tail vein injection phage display seven peptide storehouse: after MCAO model mouse Reperfu-sion 1h, by tail vein injection 1 × 10
11pfu phage display seven peptide storehouse, body-internal-circulation 1h;
3) perfusion washing: after vetanarcol intraperitoneal anesthesia, open thoracic cavity, left ventricle inserting needle perfusion PBS, fully the phage clone of non-specific binding is removed in washing;
4) solution takes brain: dissect and take out full brain, is separated ischemic side and offside half brain, drops into and is equipped with in LB liquid nutrient medium;
5) tissue homogenate release phage clone: tissue is abundant homogenate after weighing, and discharges phage clone;
6) phage clone amplification: homogenate is surveyed titre, residue homogenate add be in logarithmic growth early stage E.coli ER2738 culture in increase;
7) next round screening is dropped in the secondary storehouse of the phage of increasing again, same to step 1) ~ 6 of method), altogether screen and obtain the phage clone containing the polypeptide be combined with cerebral infarction tissue specificity through four-wheel.
The above-mentioned targeting of HGG polypeptide in MCAO model body be combined with cerebral infarction tissue specificity and the application in imaging.
The above-mentioned HGG polypeptide be combined with cerebral infarction tissue specificity is preparing the application in highly sensitive molecular imaging probe.
In application in preparation highly sensitive molecular imaging probe, after above-mentioned HGG polypeptide and superparamag-netic iron oxide coupling, build nuclear magnetic resonance molecular probe.
The above-mentioned HGG polypeptide be combined with cerebral infarction tissue specificity is preparing the application in targeted delivery nerve protection medicine carrier.
Beneficial effect: the present invention has the following advantages:
1, the present invention's screening obtains the HGG polypeptide of a species specificity and cerebral infarction tissue bond, has filled up the blank of the polypeptide that domestic current shortage is combined with cerebral infarction tissue specificity.
2, seven peptides that the present invention screens acquisition synthesize by manual method, and micromolecule polypeptide molecular weight is little, activity is high, penetration power is strong, specificity is high, toxicity is low, to be applicable in construct imaging molecule probe and for targeted delivery of drugs.
3, the present invention screens the HGG polypeptide obtained and all confirms to have good specificity at phage display peptide and the horizontal experiment in vivo of synthetic peptide, for solid basis has been established in the clinical front further investigation of this polypeptide.
4, the present invention screen the HGG polypeptide obtained can build specific molecular probes for cerebral infarction molecular imaging and can targeted delivery neuroprotective class medicine to neuronal cell, strengthen the neuroprotective of medicine.
Accompanying drawing explanation
Fig. 1 is in titer determination method qualification HGG-M13 body and cerebral infarction tissue bond specificity figure (* represents that P value is less than 0.05, * * and represents that P value is less than 0.001);
Fig. 2 is in phage immunofluorescence staining qualification HGG-M13 body and cerebral infarction tissue bond specificity figure (scale length represents 100 μm);
Fig. 3 is the cell type specificity qualification figure (scale length represents 100 μm) that HGG-M13 combines;
Fig. 4 is in fluorescent mark HGG polypeptide body and cerebral infarction tissue bond specificity identification figure (scale length represents 100 μm);
Fig. 5 is HGG-NPs mr molecular probe small animal living body image in MCAO model.
Embodiment
It is as follows that experiment material used in embodiment, reagent and agent prescription are led in the present invention:
Major experimental material:
1, phage display peptide library Ph.D.-7: purchased from New England BioLabs company.Complexity ~ 2.7 × 10
9individual transformant.Its-96gIII sequencing primer is 5 '-
hOcCC TCA TAG TTA GCG TAA CG-3 '.With storehouse with Host Strains E.coli ER2738 be the male intestinal bacteria of tetracyclin resistance, provide with the yeast culture thing form containing 50% glycerine.
2, C57 mouse: male, 20g body weight, purchased from Military Medical Science Institute, raises in Southeast China University SPF level Animal House.
Main agents and formula:
Main agents
1, phage display peptide library screening main agents: X-gal, DMF, NaN
3, Tween-20, BSA, glycine, tsiklomitsin is all purchased from Amresco; Peptone, yeast extract are purchased from OXOID.
2, specificity identification main agents: HRP marks mouse-anti M13 antibody purchased from Parmacia company; AlexaFluor 555 marks goat anti-mouse antibody purchased from Molecular Probes company; Rabbit anti-mouse NeuN (neurone Marker) and rabbit anti-mouse GFAP antibody (astroglia cell Marker) are purchased from Millipore company.Main agents is filled a prescription
1, LB substratum: often liter contains 10g Bacto-Tryptone (bacto-tryptone), 5g yeast extract (yeast extract paste), 5g NaCl.Autoclaving, room temperature storage.
2, LB/IPTG/Xgal is dull and stereotyped: LB substratum+15g/L agar powder.Autoclaving, when being cooled to lower than 70 DEG C, adds 1mL IPTG/Xgal, and mixing is down flat plate.Dull and stereotyped 4 DEG C of stored protected from light.
3, top-agar: often liter contains 10g Bacto-Tryptone, 5g yeast extract, 5g NaCl, 1gMgCl
26H
2o, 7g agar powder.Autoclaving, is divided into 5mL equal portions.Solid medium room temperature storage, used time microwave oven melts.
4, tsiklomitsin storage liquid: be dissolved in 50% ethanol with the concentration of 20mg/mL.-20 DEG C of stored protected from light.With front shaking up.
5, LB-Tet is dull and stereotyped: LB substratum+15g/L agar powder.Autoclaving, when being cooled to lower than 70 DEG C, add 1mL tsiklomitsin storage liquid, mixing is down flat plate.Dull and stereotyped 4 DEG C of stored protected from light.
6, PBS: often liter containing NaCl:8.00g, KCl:0.20g, Na
2hPO
412H
2o:3.58g, KH
2pO
4: 0.24g, PH=7.2.Autoclaving, storage at room temperature.
7、PEG/NaCl：20％(w/v)PEG-8000，2.5M NaCl。Autoclaving, room temperature storage.
8, iodide damping fluid: 10mM Tris-HCl (pH 8.0), 1mM EDTA, 4M NaI.Room temperature stored protected from light.
9, IPTG/X-gal formula: 1.25g IPTG (isopropyl β – D-thiogalactoside) and 1g X-gal is dissolved in 25mL dimethyl formamide.Solution-20 DEG C of stored protected from light.
Be more than main raw used and reagent in the present invention's 8 embodiments.Introduce embodiment in detail below.
The screening of embodiment 1HGG polypeptide and preparation
This example adopts phage display peptide library triage techniques in body to obtain the HGG polypeptide be combined with cerebral infarction tissue specificity, and concrete steps are as follows:
1, MCAO model construction: C57 mouse 0.4% vetanarcol (40mg/kg) intraperitoneal injection of anesthesia, dorsal position is fixed.Neck median line otch, along nutator inner edge separating muscle and manadesma, is separated right carotid (CCA), external carotid artery (ECA) and internal carotid artery (ICA).Proximal part ligation CCA, distal end ligation ECA, temporarily press from both sides with arteriole folder and close ICA, then an osculum is cut at ECA furcation 2mm place, line will be fastened and be inserted into ICA, and touch with fiber surgical tweezer and fasten line, from vascular bifurcation place, calculate distance, when depth of penetration is at 1cm, tightly fasten the fine rule of ECA distal end.Ischemic 1h, unties the fine rule of ECA distal end, is extracted by bolt line gently, tightly fastens the fine rule of ECA distal end immediately, prevents hemorrhage.Meanwhile, unclamp CCA proximal part fine rule, recover CCA blood supply.By Longa method, Neuroscore is carried out to model.Longa method Neuroscore divides 5 grades: 0 point, normally, and impassivity functional impairment; 1 point, left side fore paw can not full extension, slight neurologic impairment; 2 points, during walking, (paralysis side) turn-takes to the left, moderate neurologic impairment; 3 points, during walking, health to the left (paralysis side) is toppled over, severe neurological functional impairment; 4 points, spontaneously can not walk, lose consciously.The MCAO model mouse (moderate neurologic impairment) choosing Neuroscore 2 points carries out the screening of phage display peptide library in body.
2, tail vein injection phage display seven peptide storehouse: after MCAO model mouse Reperfu-sion 1h, by tail vein injection 1 × 10
11pfu phage display seven peptide storehouse, body-internal-circulation 1h.
3, perfusion washing: after 0.4% vetanarcol intraperitoneal anesthesia, open thoracic cavity, left ventricle inserting needle perfusion PBS adds up to 200mL, and fully the phage clone of non-specific binding is removed in washing.
4, solution takes brain: dissect and take out full brain, is separated ischemic side and offside half brain, drops into and is equipped with in the 1.5mL Eppendorf pipe of 500 μ L LB liquid nutrient mediums.
5, tissue homogenate release phage clone: tissue is abundant homogenate after weighing, and discharges phage clone.
6, phage clone amplification: homogenate is surveyed titre, residue homogenate add be in logarithmic growth early stage 20mL E.coli ER2738 culture in increase.
7, the secondary storehouse of phage after amplification is used for next round screening, and screening method is the same; Wherein, the phage that the screening of N wheel drops into is the secondary storehouse of phage after N-1 takes turns elutriant amplification;
After four-wheel screening, LB/IPTG/Xgal flat board measures fourth round elutriation gained homogenate titre.From fourth round screening gained homogenate titre plate with sterilizing toothpick or suction nozzle picking 120 blue plaques in the E.coli ER2738 culture tube to 1mL logarithmic growth early stage, amplification monoclonal phage.
According to the titre of often taking turns screening phage homogenate, calculate yield and the enrichment of every g tissue.The phage number that the yield that every g organizes=every g tissue reclaims/total input phage number.Yield/the (n-1)th that enrichment=the n-th takes turns screening every g tissue takes turns the yield (n >=2) of screening every g tissue.
Selective Pressure and the enrichment condition of whole screening process are as shown in table 1, after four-wheel screening, add up to be enriched 10.4 times with the phage clone of cerebral infarction tissue bond.
The Selective Pressure screened in the polypeptide body of table 1 and cerebral infarction tissue bond controls and the enrichment condition of phage clone
Embodiment 2 phage mono-clonal DNA extraction and sequencing
The present embodiment extracts 120 monoclonal DNA of candidate phage and carries out sequencing.
After in embodiment 1, the monoclonal phage of picking increases, centrifugal segregation bacterium, gets 500 μ L phage supernatants and adds 200 μ L PEG/NaCl, mixing leaves standstill 10min on ice, 4 DEG C of centrifugal 10min of 14000rpm, throw out is thoroughly resuspended in 100 μ L iodide damping fluids, adds 250 μ L ethanol, after incubation at room temperature 10min, centrifugal 10min, abandons supernatant, washes precipitation with 70% ethanol, of short duration vacuum-drying postprecipitation is resuspended in 30 μ L TE, checks order.
In the present embodiment, all order-checkings complete by Hua Da gene.Sequencing primer be-96gIII:5 '-
hOgTA TGGGAT TTT GCT AAA CAA C-3 '.
Utilize SeqMan software analysis phage clone sequencing result, and according to genetic codon table, base sequence is translated as aminoacid sequence.Statistics finds that successful 106 phage clones of order-checking have 17 kinds of sequences, wherein has 59 phage clones to carry external source insertion sequence as shown in SEQ ID NO:1, accounts for 55.66%, called after HGG.
The synthesis of embodiment 3HGG polypeptide and fluorescent decoration
HGG polypeptide passes through chemical process synthetic by the biochemical (Shanghai) Co., Ltd. of gill according to described aminoacid sequence.Synthetic product, by high performance liquid chromatography (HPLC) purifying, is identified through mass spectrum (MS).The purity of polypeptide of the present invention is all more than 95%.
HGG polypeptide fluorescent mark is completed by the biochemical (Shanghai) Co., Ltd. of gill.Modification mode is that HGG peptide-COOH holds increase Methionin K, is connected with 5-TAMRA fluorescence dye by its side-chain amino group.5-TAMRA fluorescent mark peptide of the present invention is by high performance liquid chromatography (HPLC) purifying, and through mass spectrum (MS) qualification, purity is all more than 95%.
Embodiment 4HGG polypeptide physico-chemical property
The ProtParam tool (http://web.expasy.org/protparam/) that the present embodiment utilizes ExPASy website to provide analyzes HGG polypeptide physico-chemical property.As shown in table 2, this polypeptide molecular weight is 800.9, and theoretical iso-electric point is 8.75, and be by 113 atomic buildings, be about 3.5h in the mammiferous reticulocyte transformation period, this polypeptide is more stable, and this polypeptide liposoluble coefficient is 97.14, and overall average wetting ability is-0.257.
Table 2 HGG peptide physicochemical characteristics is analyzed
Embodiment 5HGG-M13 phage-peptide clone and cerebral infarction tissue bond specificity identification
The present embodiment chooses the phage of carrying HGG external source Insert Fragment-peptide clone (called after HGG-M13), by feeding back the specificity of experimental identification itself and cerebral infarction tissue bond in phage body.
1. the specificity of titer determination method qualification HGG-M13
Build MCAO model, tail vein injection 1 × 10
11pfu phage, isoflurane anesthesia after circulation 1h, left ventricle PBS perfusion 200mL, is divided into two after the full brain of anatomical isolation (ischemic side and offside), tissue homogenate after weighing, release phage.Measure phage titre.Calculate and the titre value organizing pnagus medius of comparative unit quality.Experimental group injection HGG-M13 in this experiment, control group injection is containing the Insertless-M13 of external source Insert Fragment, and sham operated rats is fastened line and to be inserted in neck but not enter brain.
As shown in Figure 1, HGG-M13 is in MCAO model group, and the titre value of ischemic homonymy unit mass (g) cerebral tissue is significantly higher than offside cerebral tissue, and the two ratio is 1.85, and difference has statistical significance.In sham operated rats, HGG-M13 does not have significant difference in the distribution of ischemic homonymy and offside cerebral tissue.These results suggest that the specificity of HGG-M13 and cerebral infarction tissue bond.Meanwhile, the titre in the cerebral tissue of ischemic homonymy HGG-M13 in unit mass is also significantly higher than the titre of Insertless-M13, and further illustrating that HGG-M13 is combined with ischemic stroke tissue specificity is the Insert Fragment HGG depending on external source.
2. the specificity of immunofluorescence technique qualification HGG-M13
Build MCAO model, tail vein injection 1 × 10
11pfu phage, isoflurane anesthesia after circulation 1h, left ventricle perfusion PBS 200mL fully removes unconjugated phage clone, continues 4%PFA 50mL perfusion fixing, the full brain of anatomical isolation, and saccharose gradient dehydration after PFA spends the night and fixes, OCT embeds, frozen section.Frozen section tissue and mouse-anti M13 antibody 37 DEG C hatch 1h, after washing 6 times, add Alexa Fluor 555 fluorescent mark anti-mouse two and resist, hatch 1h for 37 DEG C.After washing 6 times, DAPI carries out nuclear targeting, and mounting is observed.
As shown in Figure 2, there is obvious HGG-M13 red fluorescent at MCAO model ischemia homonymy, and far above offside fluorescence signal intensity, the distribution of specific of HGG-M13 in cerebral apoplexy ischemic side is described.Meanwhile, the fluorescent signal of HGG-M13 in cerebral apoplexy ischemic side, apparently higher than the fluorescent signal of Control-M13, further illustrates the specificity of HGG-M13 and ischemic stroke tissue bond, and this species specific combination is the Insert Fragment HGG depending on external source.
The cell type specificity qualification that embodiment 6HGG-M13 combines
The present embodiment studies the common positioning scenarios of HGG-M13 and neurone and astroglia cell by the two dyeing method of immunofluorescence, the cell type specificity that qualification HGG-M13 combines.Build MCAO model, tail vein injection 1 × 10
11pfu phage-peptide HGG-M13, isoflurane anesthesia after circulation 1h, left ventricle perfusion PBS 200mL fully removes unconjugated phage clone, continue 4%PFA 50mL perfusion fixing, the full brain of anatomical isolation, saccharose gradient dehydration after PFA spends the night and fixes, OCT embeds, frozen section.Frozen section tissue and mouse-anti M13 antibody and rabbit anti-mouse NeuN (neurone Marker) or rabbit anti-mouse GFAP antibody (astroglia cell Marker) 37 DEG C hatch 1h, after washing 6 times, add the anti-and Alexa Fluor 488 fluorescent mark anti-rabbit two of Alexa Fluor 555 fluorescent mark anti-mouse two to resist, hatch 1h for 37 DEG C.After washing 6 times, DAPI carries out nuclear targeting, and mounting is observed.
As shown in Figure 3, locate altogether at the fluorescent signal of MCAO model ischemia homonymy HGG-M13 and NeuN (neurone Marker), and do not mark altogether with GFAP (astroglia cell Marker), illustrate that the main neuronal cell in ischemic stroke tissue of HGG-M13 is combined.The neuronal cell of HGG-M13 in ischemic stroke tissue is combined points out this peptide section to may be used for targeted delivery nerve protection medicine, neurone impaired after better protection cerebral ischemia.
The HGG peptide of embodiment 7 external source synthesis and the specificity of cerebral infarction tissue bond
Build MCAO model, tail vein injection fluorescent mark HGG peptide HGG-(5-TAMRA), isoflurane anesthesia after circulation 15min, left ventricle perfusion PBS 100mL fully removes unconjugated peptide section, continue 4%PFA 50mL perfusion fixing, the full brain of anatomical isolation, saccharose gradient dehydration after PFA spends the night and fixes, OCT embeds, frozen section.DAPI carries out nuclear targeting, and mounting is observed.
As shown in Figure 4, obvious HGG-(5-TAMRA) red fluorescent is had at MCAO model ischemia homonymy, and far above offside fluorescence signal intensity, and in sham operated rats, HGG-(5-TAMRA) fluorescent signal is not obvious, and the distribution of specific of HGG peptide in cerebral apoplexy ischemic side is described.Meanwhile, the fluorescent signal of HGG polypeptide in cerebral apoplexy ischemic side, apparently higher than the fluorescent signal of control peptide GGG-(5-TAMRA), further illustrates the specificity of HGG polypeptide and ischemic stroke tissue bond.
The structure of embodiment 8HGG polypeptide MRI molecular imaging probe, sign and Micro-MRI imaging
HGG polypeptide coupling paramagnetic iron oxide nano particle is built mr molecular probe and is used for cerebral apoplexy ischemic rat brain Micro-MRI imaging by the present embodiment.The molecular probe called after HGG-NPs of synthesis.Characterized this molecular probe by ordinary method, it is 187nm that result shows this probe hydration particle diameter average, has good magnetic resonance radiography usefulness.
Build MCAO model, tail vein injection fluorescent mark HGG-NPs and non-target tropism contrast probe NPs, at the capable magnetic resonance imaging of Preset Time point, scanning sequence is the turboRARE-T2 sequence of T2WI, and to be parameter be parameter: TR 2500ms, TE 50ms, FOV 2.0 × 2.0cm, 180 °, angle of twist (FA), matrix 256 × 256, thickness 1mm.
As shown in Figure 5, HGG-NPs probe injection 30min can find obvious dark signal in cerebral infarction tissue, along with time lengthening, HGG-NPs is initiatively enrichment gradually in cerebral infarction tissue, illustrates that probe has good specificity and active targeting.But not targeting contrast probe NPs organizes at cerebral infarction, does not have obvious signal distributions, further illustrates the specificity of HGG-NPs molecular probe.The prompting of this embodiment can build specific molecular probes, for the imaging of cerebral infarction tissue element based on HGG polypeptide.
The above is only the preferred embodiment of the present invention; be noted that for those skilled in the art; under the premise without departing from the principles of the invention, can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (8)
1. the HGG polypeptide be combined with cerebral infarction tissue specificity, is characterized in that, the aminoacid sequence of described HGG polypeptide is as shown in SEQ ID NO:1.
2. the HGG polypeptide be combined with cerebral infarction tissue specificity according to claim 1, it is characterized in that, described HGG polypeptide molecular weight is 800.9, theoretical iso-electric point is 8.75, by 113 atomic buildings, be 3.5h in the mammiferous reticulocyte transformation period, this polypeptide liposoluble coefficient is 97.14, and overall average wetting ability is-0.257.
3. the HGG polypeptide be combined with cerebral infarction tissue specificity according to claim 1, is characterized in that, described HGG polypeptide is obtained by phage display peptide library triage techniques in body, and is obtained by a large amount of stdn synthesis of chemical process.
4. the screening method of HGG polypeptide according to claim 1, is characterized in that, comprise the following steps:
1) MCAO model mouse builds;
2) tail vein injection phage display seven peptide storehouse: after MCAO model mouse Reperfu-sion 1h, by tail vein injection 1 × 10
11pfu phage display seven peptide storehouse, body-internal-circulation 1h;
3) perfusion washing: after vetanarcol intraperitoneal anesthesia, open thoracic cavity, left ventricle inserting needle perfusion PBS, fully the phage clone of non-specific binding is removed in washing;
4) solution takes brain: dissect and take out full brain, is separated ischemic side and offside half brain, drops into and is equipped with in LB liquid nutrient medium;
5) tissue homogenate release phage clone: tissue is abundant homogenate after weighing, and discharges phage clone;
6) phage clone amplification: homogenate is surveyed titre, residue homogenate add be in logarithmic growth early stage E.coli ER2738 culture in increase;
7) next round screening is dropped in the secondary storehouse of the phage of increasing again, same to step 1) ~ 6 of method), altogether screen and obtain the phage clone containing the HGG polypeptide be combined with cerebral infarction tissue specificity through four-wheel.
5. the targeting of HGG polypeptide in MCAO model body that be combined with cerebral infarction tissue specificity according to claim 1 and the application in imaging.
6. the HGG polypeptide be combined with cerebral infarction tissue specificity according to claim 1 is preparing the application in highly sensitive molecular imaging probe.
7. application according to claim 6, is characterized in that, builds nuclear magnetic resonance molecular probe after described HGG polypeptide and superparamag-netic iron oxide coupling.
8. the HGG polypeptide be combined with cerebral infarction tissue specificity according to claim 1 is preparing the application in targeted delivery nerve protection medicine carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510011387.5A CN104592352B (en) | 2015-01-09 | 2015-01-09 | The HGG polypeptides combined with cerebral arterial thrombosis tissue specificity and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510011387.5A CN104592352B (en) | 2015-01-09 | 2015-01-09 | The HGG polypeptides combined with cerebral arterial thrombosis tissue specificity and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104592352A true CN104592352A (en) | 2015-05-06 |
| CN104592352B CN104592352B (en) | 2017-08-15 |
Family
ID=53118443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510011387.5A Expired - Fee Related CN104592352B (en) | 2015-01-09 | 2015-01-09 | The HGG polypeptides combined with cerebral arterial thrombosis tissue specificity and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104592352B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3179251A1 (en) * | 2015-12-08 | 2017-06-14 | Agricultural Technology Research Institute | Cancer stem cell targeting peptides and use thereof |
| WO2018139665A1 (en) * | 2017-01-30 | 2018-08-02 | 国立研究開発法人国立循環器病研究センター | Use for peptide uniquely binding to vascular endothelial cells, and peptide |
| TWI683828B (en) * | 2016-12-08 | 2020-02-01 | 財團法人農業科技研究院 | Cancer stem cell targeting peptide and use thereof |
| CN113248569A (en) * | 2021-06-18 | 2021-08-13 | 中国科学院苏州纳米技术与纳米仿生研究所 | Leptin receptor affinity peptide and application thereof |
| JP2022017562A (en) * | 2017-01-30 | 2022-01-25 | 国立研究開発法人国立循環器病研究センター | Use of peptide specifically binding to vascular endothelial cells and peptide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214169A (en) * | 2008-01-14 | 2008-07-09 | 河北医科大学第二医院 | Method for establishing rat hemorrhagic cerebral infarction animal model by collagenase revulsion |
| EP2186821A1 (en) * | 2008-11-11 | 2010-05-19 | Universität Ulm | Protein with promoting effects for axonal growth of neurons of central nervous system |
-
2015
- 2015-01-09 CN CN201510011387.5A patent/CN104592352B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214169A (en) * | 2008-01-14 | 2008-07-09 | 河北医科大学第二医院 | Method for establishing rat hemorrhagic cerebral infarction animal model by collagenase revulsion |
| EP2186821A1 (en) * | 2008-11-11 | 2010-05-19 | Universität Ulm | Protein with promoting effects for axonal growth of neurons of central nervous system |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3179251A1 (en) * | 2015-12-08 | 2017-06-14 | Agricultural Technology Research Institute | Cancer stem cell targeting peptides and use thereof |
| CN107033216A (en) * | 2015-12-08 | 2017-08-11 | 财团法人农业科技研究院 | Peptides targeting cancer stem cells and uses thereof |
| JP2017141219A (en) * | 2015-12-08 | 2017-08-17 | アグリカルチュラル・テクノロジー・リサーチ・インスティテュートＡｇｒｉｃｕｌｔｕｒａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | Cancer stem cell-targeting peptide and use thereof |
| TWI623552B (en) * | 2015-12-08 | 2018-05-11 | 財團法人農業科技研究院 | Cancer stem cell targeting peptide and use thereof |
| CN107033216B (en) * | 2015-12-08 | 2021-08-03 | 财团法人农业科技研究院 | Peptides targeting cancer stem cells and uses thereof |
| TWI683828B (en) * | 2016-12-08 | 2020-02-01 | 財團法人農業科技研究院 | Cancer stem cell targeting peptide and use thereof |
| JP2018121760A (en) * | 2017-01-30 | 2018-08-09 | 国立研究開発法人国立循環器病研究センター | Use of peptide specifically binding to vascular endothelial cells and peptide |
| WO2018139665A1 (en) * | 2017-01-30 | 2018-08-02 | 国立研究開発法人国立循環器病研究センター | Use for peptide uniquely binding to vascular endothelial cells, and peptide |
| JP2022017562A (en) * | 2017-01-30 | 2022-01-25 | 国立研究開発法人国立循環器病研究センター | Use of peptide specifically binding to vascular endothelial cells and peptide |
| JP7017726B2 (en) | 2017-01-30 | 2022-02-09 | 国立研究開発法人国立循環器病研究センター | Use of peptides that specifically bind to vascular endothelial cells, and peptides |
| US11253626B2 (en) | 2017-01-30 | 2022-02-22 | National Cerebral And Cardiovascular Center | Use for peptide uniquely binding to vascular endothelial cells, and peptide |
| JP7320796B2 (en) | 2017-01-30 | 2023-08-04 | 国立研究開発法人国立循環器病研究センター | Use of peptide that specifically binds to vascular endothelial cells, and peptide |
| CN113248569A (en) * | 2021-06-18 | 2021-08-13 | 中国科学院苏州纳米技术与纳米仿生研究所 | Leptin receptor affinity peptide and application thereof |
| CN113248569B (en) * | 2021-06-18 | 2021-10-12 | 中国科学院苏州纳米技术与纳米仿生研究所 | Leptin receptor affinity peptide and application thereof |
| WO2022262509A1 (en) * | 2021-06-18 | 2022-12-22 | 江苏独步生物科技有限公司 | Leptin receptor affinity peptide and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104592352B (en) | 2017-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6553105B2 (en) | Chlorotoxin variants, conjugates and methods of using them | |
| CN104592352A (en) | HGG (Human Gammaglobulin) polypeptide in combination with tissue specificity of cerebral arterial thrombosis and application thereof | |
| CN102743770B (en) | A kind of targeting molecule image probe and living body molecule imaging method | |
| CN107148425A (en) | Bicyclic peptide ligand specific to MT1 MMP | |
| US20200138980A1 (en) | Methods and compositions for the detection of cancer | |
| Li et al. | Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer | |
| CN104250287B (en) | Tumor targeting polypeptide and application | |
| WO2007011680A2 (en) | Ligands to radiation-induced molecules | |
| CN114933633B (en) | Natural peptide probe for specifically recognizing FGFR4 and application thereof | |
| CN108473541A (en) | Pass through the peptide compounds and peptide conjugate of receptor-mediated regimen chemotherapy cancer | |
| CN110312517A (en) | Luteinising hormone-releasing hormo receptor (LHRH-R) conjugate and application thereof | |
| CN112961215B (en) | Polypeptide and tumor targeting peptide, tumor detection reagent, tumor surgery navigation contrast medium and tumor targeting drug thereof | |
| CN104774247A (en) | Integrin receptor alpha-v-beta-3 related 5-peptide | |
| Lin et al. | In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5. 5 | |
| CN103998929A (en) | Method for patient selection | |
| Guo et al. | Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides | |
| CN105859846A (en) | Polypeptide having binding affinity to HPV16 E7 and application thereof | |
| CN110357945A (en) | A kind of Coxsackie virus/adenovirus the simulating peptide and its application of target tumor | |
| De et al. | Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor | |
| CN116023438A (en) | CXCR4 targeting polypeptide and application thereof | |
| WO2023044965A1 (en) | Snap-tag probe, and preparation method therefor and use thereof | |
| CN116063379A (en) | EphA2 targeting polypeptides and uses thereof | |
| CN101503473A (en) | Targeted polypeptide for diagnosing and treating lung cancer in vivo and in vitro and use thereof | |
| CN113817023A (en) | FGFR 4-targeted affinity peptide and application thereof | |
| CN106632613A (en) | Affinity peptide related to coxsackie adenovirus receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170815 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |